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Research
AbstrACt
Objectives To describe the perspectives of clinicians and 
researchers on identifying, establishing and implementing 
core outcomes in haemodialysis and their expected 
impact.
Design Face-to-face, semistructured interviews; thematic 
analysis.
stetting Twenty-seven centres across nine countries.
Participants Fifty-eight nephrologists (42 (72%) who 
were also triallists).
results We identified six themes: reflecting direct 
patient relevance and impact (survival as the primary 
goal of dialysis, enabling well-being and functioning, 
severe consequences of comorbidities and complications, 
indicators of treatment success, universal relevance, 
stakeholder consensus); amenable and responsive to 
interventions (realistic and possible to intervene on, 
differentiating between treatments); reflective of economic 
burden on healthcare; feasibility of implementation (clarity 
and consistency in definition, easily measurable, requiring 
minimal resources, creating a cultural shift, aversion to 
intensifying bureaucracy, allowing justifiable exceptions); 
authoritative inducement and directive (endorsement for 
legitimacy, necessity of buy-in from dialysis providers, 
incentivising uptake); instituting patient-centredness 
(explicitly addressing patient-important outcomes, 
reciprocating trial participation, improving comparability 
of interventions for decision-making, driving quality 
improvement and compelling a focus on quality of life).
Conclusions Nephrologists emphasised that core 
outcomes should be relevant to patients, amenable 
to change, feasible to implement and supported by 
stakeholder organisations. They expected core outcomes 
would improve patient-centred care and outcomes.
IntrODuCtIOn 
The value of randomised trials for informing 
practice and policy is currently limited by the 
inconsistency of outcomes that are reported, 
which can prevent meaningful assessment of 
the comparative effectiveness of interventions 
across trials. There is a tendency to measure 
and report outcomes that are expected to 
be responsive to the intervention and those 
that are easy to measure rather than what is 
important to decision making.1–3 Biochem-
ical or surrogate endpoints, which are usually 
easier and feasible to measure, are frequently 
reported instead of ‘patient-important’ 
outcomes such as mortality and quality of life 
that are directly relevant to patients and clini-
cians for shared decision-making.4 5 Without 
standardised outcomes, outcome reporting 
may be biased, whereby researchers selec-
tively report outcomes that show positive 
results and may lead to patient harm.6 7 
The problems with outcome reporting in 
trials have been increasingly recognised and 
resulted in concerted efforts to establish core 
outcome sets.2 8 A core outcome set is defined 
as an agreed standardised set of outcomes 
that should be measured and reported, as 
a minimum, in all clinical trials in specific 
areas of health or healthcare.3 To date, more 
than 900 core outcomes studies have been 
strengths and limitations of this study
 ► Face-to-face, semistructured interviews were con-
ducted with nephrologists purposively sampled 
across nine countries to obtain in-depth and diverse 
data on their perspectives on establishing core out-
comes for trials in patients on haemodialysis.
 ► The range of perspectives and challenges ob-
tained will inform the development and implemen-
tation of core outcomes to be used in all trials in 
haemodialysis.
 ► Nephrologists were all interviewed in English lan-
guage and we focused on haemodialysis, which may 
potentially limit transferability of the findings.
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registered in the Core Outcome Measures in Effective-
ness Trials (COMET) database.9 Although specific core 
outcome sets in rheumatology (such as tender joints, 
swollen joins, pain, physician and patient global assess-
ment and physical disability for rheumatoid arthritis) 
developed through the long-established Outcome 
Measures in Rheumatology (OMERACT) initiative have 
been shown to be increasingly used in trials,10 evaluations 
of the uptake of core outcomes are few in number and 
show variable results.10–14
The implementation of core outcomes requires exten-
sive stakeholder engagement, and specifically, end-users 
(eg, triallists who use them and clinicians who apply 
the results) need to be involved in the process of estab-
lishing core outcomes.15 In recent studies, developers 
of core outcome sets have been interviewed to inform 
guidance for the conduct of core outcomes studies.2 15 
However, the perspectives of end-users on the concept, 
identification and expected impact of core outcomes 
remain largely unknown. For example, the clinicians’ 
acceptance and role in advocating for core outcomes in 
clinical trials may impact on the implementation of core 
outcomes.
In the context of dialysis, for example, nephrologists 
can provide relevant insights on establishing and imple-
menting core outcomes because of their direct role in 
patient care and involvement in trials. The aim of this 
study was to describe the attitudes and perspectives of 
nephrologists on outcomes that should be included in 
a core outcome set for haemodialysis, the implementa-
tion of core outcomes in trials in haemodialysis and their 
expected impact. This may inform strategies and mecha-
nisms for implementing core outcomes in trials in haemo-
dialysis and potentially in other settings.
MethODs
Context
The international Standardised Outcomes in Nephrology 
(SONG) Initiative commenced in November 2014 to 
establish core outcomes across the spectrum of chronic 
kidney disease, with an initial focus on haemodialysis.16–19 
As part of the SONG Initiative and prior to establishing 
the final core outcome set for haemodialysis (which 
included mortality, cardiovascular disease, fatigue and 
vascular access), interviews were conducted with nephrol-
ogists and this article focuses on the attitudes, expecta-
tions and opinions of nephrologists on establishing and 
implementing core outcomes in haemodialysis. Of note, 
core outcomes are to be reported in all trials within a 
given area because they have been explicitly identified by 
patients, caregivers and health professionals to be criti-
cally important for decision-making. The outcome is of 
importance to patients, even if the results of a particular 
trial show no difference in the outcome.’ We used the 
Consolidated Criteria for Reporting Qualitative Health 
Research (COREQ) to report this study20 (online supple-
mentary file 1).
Participant selection
Nephrologists involved in providing care for adults on 
haemodialysis were eligible to participate. We identified 
potential participants via our collegial and professional 
networks and asked a nominated nephrologist at each city 
internationally (London, Oxford, Cambridge, UK; Brus-
sels, Belgium; Vienna, Austria; Berlin, Germany; Calgary, 
Canada; Houston, USA) to identify potential partici-
pants at their institution. Using a purposive sampling 
strategy, we selected participants to include a diverse 
range of demographic characteristics (age, gender, loca-
tion), clinical experience (years of clinical experience 
in nephrology, size of haemodialysis unit) and research 
experience (involvement as an investigator in clinical 
trials and systematic reviews). All participants provided 
written informed and voluntary consent to participate.
Data collection
The interview guide was developed based on a litera-
ture review on core outcomes and discussion among the 
investigators (online supplementary file 2). Participants 
were asked what outcomes they believed were important 
to include in all trials in haemodialysis and their atti-
tudes and beliefs about establishing and implementing 
core outcomes for haemodialysis. We defined a core 
outcome set as an agreed minimum set of outcomes to 
be measured and reported in all trials in a specific area,3 
that is, in patients on haemodialysis. The first author (AT) 
conducted face-to-face semistructured interviews at office 
and conference venues during May to October 2015 until 
data saturation across all interview topics was reached. 
All interviews conducted in English, audio-recorded and 
transcribed verbatim.
Data analysis
The transcripts were imported into HyperRESEARCH 
software V.3.3 (ResearchWare, USA). Thematic anal-
ysis involves identifying, examining, coding, comparing 
and grouping concepts to develop themes that describe 
the phenomenon being investigated and addresses the 
research question.21 Using thematic analysis, AT coded 
the transcripts line-by-line and inductively coded concepts 
relevant to the participant perspectives on establishing 
and implementing core outcomes in haemodialysis. The 
preliminary codes were reviewed by authors (TG, EO’L, 
AJ, AV) who independently read the transcripts and 
discussed any feedback with AT. This form of investigator 
triangulation can enhance the analytical framework and 
ensure that the full range and depth of data were captured 
in the initial analysis. We grouped similar concepts into 
themes and identified patterns, broader overarching 
concepts and links among the concepts and mapped 
these into a thematic schema. Preliminary findings were 
sent to participants for feedback (member-checking).
Patient and public involvement
Author TH is a patient who is one the SONG-HD Executive 
Committee and was involved in developing the research 
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question, the design of this study and the data analysis. 
Patients were not involved in the recruitment and data 
collection as this was an interview study conducted with 
nephrologists.
results
Participant characteristics
Of the 60 approached, 58 (97%) nephrologists from 
27 dialysis units across nine countries were interviewed 
(table 1). Two did not participate because of conflicting 
schedules. Most participants (n=42, 72%) had conducted 
at least one clinical trial of whom 11 (19%) had been an 
investigator on more than 10 trials and 17 (29%) partic-
ipants had published a systematic review. The mean 
duration of the interviews was 40 min. Fifty (86%) were 
conducted at a hospital (office or meeting room) and 8 
(14%) at conference venues.
themes
We identified six main themes: reflecting direct patient 
relevance and impact; amenable and responsive to inter-
ventions; burden on healthcare; feasibility for imple-
mentation; authoritative inducement and directive 
and instituting patient-centredness. The subthemes are 
described below and a thematic schema depicting how 
the themes relate to each other is provided in figure 1. 
Supporting quotations are provided in table 2.
reflecting direct patient relevance and impact
Survival as the primary goal of dialysis
The inclusion of mortality in a core outcome set was 
undisputed with participants defining this as a ‘classic 
hard endpoint’ that was ‘most important’ because of the 
‘20% 1 year’ mortality rates in haemodialysis. As nephrol-
ogists, they felt primarily responsible for patient survival 
and discussed treatments with their patients in terms of 
its risk of mortality. Dialysis was intended ‘to keep patients 
alive’ and participants asserted that they would not ‘do 
a therapy that makes people feel better but kills them 
faster’. Some suggested that, with such a high event rate, 
a difference in mortality in trials could be reasonably 
expected. Others argued that a long follow-up and a large 
sample size would be required for a trial to show a differ-
ence in mortality because of the lack of powerful potential 
interventions and noted the paucity of positive trials for 
this outcome to date. Although mortality was a critically 
important outcome for participants, they emphasised 
that patient survival should be considered in conjunction 
with quality of life outcomes and comorbidities.
Enabling well-being and functioning
In recognising the severely impaired quality of life in 
patients on haemodialysis undergoing ‘an intensive, 
time-consuming, life-altering intervention’, participants 
felt that a core outcome set must capture the impact of 
treatment on ‘physical and social functioning’ to evaluate 
the patients’ capacity to maintain independence and be 
rehabilitated. This could encompass anxiety, depression, 
stress, fatigue and pain that limited a patient’s ability 
to ‘lead a normal life’, ‘do the things they want to’ and 
achieve life goals such as sustaining gainful employment, 
reaching educational milestones and having a family. 
Some participants, however, felt that these concepts were 
difficult to measure or may not be relevant to specific 
trials that did not target quality of life outcomes.
Table 1 Participant demographic characteristics (n=58)
Characteristics N (%)
Sex
  Men 43 (74)
  Women 15 (26)
Age group (years)
  30–39 14 (24)
  40–49 20 (34)
  50–59 18 (31)
  ≥60–69 6 (10)
Years of experience in haemodialysis
  ≤10 14 (24)
  11–20 22 (38)
  >20 22 (38)
Country
  UK 14 (24)
  Australia 13 (22)
  Belgium 8 (14)
  USA 7 (12)
  Austria 5 (7)
  Canada 4 (7)
  Germany 4 (7)
  Singapore 2 (3)
  New Zealand 1 (2)
Size of dialysis unit—number of current patients on 
haemodialysis
  1–50 5 (7)
  51–100 5 (7)
  101–200 10 (17)
  201–300 9 (16)
  301–400 4 (7)
  >400 25 (43)
Number of trials as investigator
  0 16 (28)
  1–5 18 (30)
  6–10 13 (22)
  11–15 6 (10)
  >15 5 (9)
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Severe consequences of comorbidities and complications
The very high prevalence of life-threatening comorbidi-
ties in the haemodialysis population was viewed by partic-
ipants as strong justification for their inclusion as core 
outcomes. They consistently emphasised cardiovascular 
disease as the ‘greatest threat to haemodialysis patients 
… the number one reason that patients die’ and a key 
driver for hospitalisations. Some explained that the risk 
of cardiovascular disease could be ‘diffuse, non-con-
crete’ to patients and thus trials needed to report cardio-
vascular disease so nephrologists could ‘communicate 
better to patients of the various adverse consequences’. 
Other complications suggested included infection, 
cancer and bone disease based on severity and need for 
hospitalisation.
Indicators of treatment success
Participants also suggested that core outcomes could 
be those that defined the success of therapy including 
vascular access function, dialysis adequacy and treatment 
failure (eg, requiring change in dialysis modality). This 
would enable them to ‘understand the treatment better 
by looking at the outcomes in different ways’.
Universal relevance
Core outcomes had to be relevant, valid and acceptable 
across patient populations and healthcare contexts and 
measurable in different jurisdictions given the variability 
in access to technology and other resources. Participants 
suggested that core outcomes required cross-cultural rele-
vance as ‘there are different beliefs about what happens 
with death and the sanctity of life’ or differences in how 
they may respond to symptoms—‘in some cultures people 
would exaggerate pain’.
Stakeholder consensus
Some participants acknowledged they were uncertain 
which outcomes would be of highest priority from the 
patient perspective and they were currently thinking about 
important outcomes ‘in a nebulous sort of way’. Thus, they 
supported systematic consensus among a broad range of 
stakeholders, including patients, physicians and policy 
makers, to identify important outcomes—‘the benefit 
of measuring it will outweigh the cost of measuring it, if 
there’s consensus around that, then that’s going to make 
the case for the benefits to measure it’.
Amenable and responsive to interventions
Realistic and possible to intervene on
For participants, a core outcome ‘should be something 
that we [nephrologists] could intervene upon’ because 
there was ‘not much point in worrying about things that 
we can’t do anything about’. For example, one participant 
doubted the feasibility of delivering an intervention that 
Figure 1 Thematic schema. Participants believed that core outcomes for haemodialysis should be directly relevant to patients 
and encompass mortality, indicators of well-being and functioning, serious comorbidities and treatment complication; those 
that consumed healthcare resources and could be potentially impacted by interventions. They emphasised that core outcomes 
should be applicable across healthcare contexts and populations. For implementation, the outcomes had to be clearly defined, 
valid and feasible though some were uncertain about whether quality of life outcomes were easily measurable. A cultural shift 
to focus on patient-important outcomes with support from external agencies was thought to facilitate uptake of core outcomes. 
The use of core outcomes was expected to strengthen patient-centred care and outcomes by compelling researchers and 
clinicians to give explicit attention to and address patient-centred outcomes.
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t 
w
ay
s.
 (U
K
) 0
18
 
               U
ni
ve
rs
al
 r
el
ev
an
ce
S
om
et
hi
ng
 t
ha
t 
is
 a
cr
os
s 
al
l c
ul
tu
re
s,
 b
ec
au
se
 y
ou
’r
e 
ta
lk
in
g 
ab
ou
t 
d
iff
er
en
t 
ki
nd
s 
of
 p
at
ie
nt
s 
ac
ro
ss
, s
om
e 
ki
nd
 o
f o
ut
co
m
e 
th
at
 a
ll 
of
 o
ur
 p
at
ie
nt
s 
fe
lt 
ve
ry
 im
p
or
ta
nt
 t
o 
th
em
, e
ve
n 
if 
th
e 
p
hy
si
ci
an
s 
d
id
n’
t.
 T
ha
t 
w
ou
ld
 b
e 
a 
va
lu
ab
le
 t
hi
ng
 t
o 
p
ut
 in
 t
he
re
. A
nd
 s
om
et
hi
ng
 t
ha
t 
co
ul
d
 b
e 
m
ea
su
re
d
 
w
ith
 a
 fa
ir 
d
eg
re
e 
of
 c
on
fid
en
ce
. (
U
S
A
) 0
05
W
ha
t 
I w
ou
ld
 li
ke
 t
o 
se
e 
is
 w
ha
t 
m
at
te
rs
 t
o 
th
e 
d
iff
er
en
t 
gr
ou
p
s 
of
 p
eo
p
le
, a
nd
 it
 m
ay
 b
e 
th
e 
tr
av
el
, a
nd
 t
he
 fr
ee
d
om
 o
f t
ra
ve
l, 
is
 a
 li
tt
le
 n
ug
ge
t 
th
at
 
yo
u 
m
ig
ht
 d
ig
 o
ut
 o
f t
hi
s 
th
at
 y
ou
 c
ou
ld
 t
he
n 
ta
ke
 b
ac
k 
to
 p
ol
ic
y 
m
ak
er
s,
 a
nd
 p
at
ie
nt
 a
d
vo
ca
te
s 
sh
ou
ld
 b
e 
ta
ki
ng
 b
ac
k 
to
 p
ol
ic
y 
m
ak
er
s.
 (U
K
) 0
19
 
               R
eq
ui
rin
g 
st
ak
eh
ol
d
er
 
co
ns
en
su
s
If 
it’
s 
a 
co
ns
en
su
s 
se
t 
of
 t
hr
ee
 o
ut
co
m
es
 t
ha
t 
m
at
ch
es
 w
ith
 t
he
 p
at
ie
nt
 c
en
tr
ed
 a
nd
 k
in
d
 o
f w
ha
t 
w
e 
al
re
ad
y 
ca
p
tu
re
, t
he
n 
I t
hi
nk
 it
’s
 r
ea
so
na
b
le
. 
(U
S
A
) 0
01
It 
sh
ou
ld
 b
e 
ev
ol
vi
ng
, p
er
io
d
ic
al
ly
 w
e 
sh
ou
ld
 c
an
va
s 
p
at
ie
nt
s 
an
d
 c
an
va
s 
in
ve
st
ig
at
or
s 
an
d
 s
ee
 w
he
re
 t
he
 o
ve
rla
p
 is
, a
nd
 p
rio
rit
is
e 
th
e 
on
es
 t
ha
t 
ov
er
la
p
. (
U
S
A
) 0
03
It 
en
su
re
s 
th
at
 r
eg
ar
d
le
ss
 o
f w
ha
t 
in
te
rv
en
tio
n 
w
e’
re
 s
tu
d
yi
ng
, w
e’
re
 g
oi
ng
 t
o 
un
d
er
st
an
d
 h
ow
 it
 im
p
ac
ts
 o
n 
w
ha
t 
w
e 
p
er
ce
iv
e 
is
 im
p
or
ta
nt
, a
nd
 
th
er
e’
s 
co
ns
en
su
s 
ar
ou
nd
 p
er
ce
iv
in
g 
as
 b
ei
ng
 im
p
or
ta
nt
 o
ut
co
m
es
. O
b
vi
ou
sl
y 
it’
s 
go
in
g 
to
 h
av
e 
th
e 
co
ns
en
su
s 
ar
ou
nd
 p
at
ie
nt
s,
 p
ro
vi
d
er
s,
 p
ol
ic
y 
m
ak
er
s,
 t
hi
nk
in
g 
it’
s 
im
p
or
ta
nt
. T
he
 b
en
efi
t 
of
 m
ea
su
rin
g 
it 
w
ill
 o
ut
w
ei
gh
 t
he
 c
os
t 
of
 m
ea
su
rin
g 
it,
 a
nd
 I 
th
in
k 
if 
th
er
e’
s 
co
ns
en
su
s 
ar
ou
nd
 t
ha
t,
 t
he
n 
th
at
’s
 g
oi
ng
 t
o 
m
ak
e 
th
e 
ca
se
 fo
r 
th
e 
b
en
efi
ts
 t
o 
m
ea
su
re
 it
, y
ou
 k
no
w
 t
ha
t 
w
e 
ca
n 
st
an
d
ar
d
is
e 
it 
re
as
on
ab
ly
 a
cr
os
s 
d
iff
er
en
t 
p
la
ce
s 
w
he
re
 it
’s
 
b
ee
n 
m
ea
su
re
d
. (
C
an
ad
a)
 0
07
C
on
tin
ue
d
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T
he
m
e
Q
uo
ta
ti
o
ns
A
m
en
ab
le
 a
nd
 r
es
p
on
si
ve
 t
o 
in
te
rv
en
tio
ns
 
               R
ea
lis
tic
 a
nd
 
p
os
si
b
le
 t
o 
in
te
rv
en
e 
on
O
ne
 o
f t
ho
se
 c
or
e 
ou
tc
om
es
 h
as
 t
o 
d
o 
w
ith
 q
ua
lit
y 
of
 li
fe
 o
th
er
w
is
e 
w
e’
re
 g
oi
ng
 t
o 
b
e 
b
ac
k 
to
 t
he
 1
98
0s
 a
nd
 9
0s
 w
he
re
 w
e 
d
id
 t
ho
se
 la
rg
e 
tr
ia
ls
 
an
d
 lo
ok
ed
 a
t 
m
or
ta
lit
y 
an
d
 m
or
b
id
ity
 a
nd
 c
ou
ld
n’
t 
sh
ow
 a
ny
 d
iff
er
en
ce
, a
nd
 le
ft
 a
ll 
th
e 
d
oc
to
rs
 w
on
d
er
in
g,
 a
re
 w
e 
re
al
ly
 d
oi
ng
 s
om
et
hi
ng
 u
se
fu
l?
 
(U
S
A
) 0
05
Yo
u 
w
an
t 
to
 b
e 
ab
le
 t
o 
in
te
rv
en
e,
 r
ig
ht
, s
o 
ha
ve
 a
 t
ar
ge
te
d
 in
te
rv
en
tio
n 
th
at
 w
ill
 c
ha
ng
e 
th
at
 o
ut
co
m
e.
 S
o 
th
os
e 
w
ou
ld
 b
e 
th
e 
tw
o 
m
ai
n 
th
in
gs
. 
(C
an
ad
a)
 0
08
 
               D
iff
er
en
tia
tin
g 
b
et
w
ee
n 
tr
ea
tm
en
ts
S
o 
d
ep
en
d
s 
on
 h
ow
 a
lig
ne
d
 t
he
y 
ar
e 
to
w
ar
d
s 
th
e 
in
te
rv
en
tio
n 
th
at
 y
ou
’r
e 
p
ro
p
os
in
g.
 (U
S
A
) 0
05
In
 t
er
m
s 
of
 d
iff
er
en
tia
tin
g 
b
et
w
ee
n 
tr
ea
tm
en
ts
, t
ha
t’s
 r
ea
lly
 im
p
or
ta
nt
. I
 w
as
 d
is
ap
p
oi
nt
ed
, s
o 
m
uc
h 
of
 t
he
 fr
eq
ue
nt
 d
ia
ly
si
s 
tr
ia
ls
 w
er
e 
ne
ga
tiv
e 
b
ec
au
se
 t
he
re
 w
as
n’
t 
re
al
ly
 e
ith
er
 t
he
 s
uf
fic
ie
nt
 s
ep
ar
at
io
n 
b
et
w
ee
n 
th
e 
ty
p
es
 o
f t
re
at
m
en
t 
or
 s
uf
fic
ie
nt
 le
ng
th
 o
f t
im
e 
on
 t
re
at
m
en
t,
 b
ut
 a
ls
o 
th
e 
ou
tc
om
es
 d
id
n’
t 
re
al
ly
 t
al
k 
to
 t
ho
se
 t
w
o 
d
iff
er
en
t 
gr
ou
p
s 
in
 q
ui
te
 t
he
 r
ig
ht
 w
ay
. (
U
K
) 0
26
R
efl
ec
tiv
e 
of
 e
co
no
m
ic
 b
ur
d
en
 o
n 
he
al
th
ca
re
W
e 
co
ns
um
e 
a 
to
n 
of
 r
es
ou
rc
es
 w
ith
 v
as
cu
la
r 
ac
ce
ss
, i
f w
e’
re
 s
m
ar
t 
ab
ou
t 
w
ho
 w
e 
p
ut
 t
he
m
 in
 a
nd
 c
an
 m
in
im
is
e 
re
so
ur
ce
 c
on
su
m
p
tio
n,
 t
ha
t’s
 a
n 
im
p
or
ta
nt
 g
oa
l. 
(C
an
ad
a)
Th
e 
th
ird
 t
hi
ng
 is
 a
b
ou
t 
ex
p
en
se
, h
ow
 m
uc
h 
it’
s 
co
st
in
g 
th
e 
ta
xp
ay
er
. (
U
K
) 0
22
It 
w
ill
 g
et
 m
or
e 
im
p
or
ta
nt
 in
 t
he
 n
ex
t 
ye
ar
s 
as
 a
 c
os
t 
to
 im
p
ro
ve
 d
ia
ly
si
s 
th
er
ap
ie
s 
w
ith
 t
he
 g
ro
w
in
g 
am
ou
nt
 o
f p
at
ie
nt
s 
w
ith
 m
or
e 
an
d
 m
or
e 
co
st
s 
an
d
 m
or
e 
co
m
or
b
id
iti
es
, i
t 
co
ul
d
 a
ls
o 
b
e 
a 
ve
ry
 im
p
or
ta
nt
 p
oi
nt
 t
o 
im
p
ro
ve
 t
ha
t.
 (G
er
m
an
y)
 0
37
Fe
as
ib
ili
ty
 o
f i
m
p
le
m
en
ta
tio
n
 
       C
la
rit
y 
an
d
 
co
ns
is
te
nc
y 
in
 
d
efi
ni
tio
n
W
e 
al
w
ay
s 
th
in
k 
ou
r 
d
efi
ni
tio
n 
is
 t
he
 b
es
t 
as
 a
 r
es
ea
rc
he
r. 
It 
p
ro
b
ab
ly
 w
ill
 b
e 
d
iffi
cu
lt 
to
 s
el
l t
o 
ev
er
yo
ne
 t
o 
us
e 
ju
st
 t
hi
s 
d
efi
ni
tio
n 
or
 t
hi
s 
st
an
d
ar
d
is
ed
 o
ut
co
m
e,
 b
ut
 a
s 
lo
ng
 a
s 
yo
u 
us
e 
so
m
e 
st
an
d
ar
d
is
ed
 d
efi
ni
tio
ns
, a
nd
 t
he
n 
if 
yo
u 
re
al
ly
 fe
lt 
st
ro
ng
ly
 a
b
ou
t 
yo
ur
 o
w
n 
d
efi
ni
tio
n 
th
at
 y
ou
 
w
an
te
d
 t
o 
us
e,
 y
ou
 c
an
 t
es
t 
th
at
 t
oo
. B
ut
 it
 w
ou
ld
 b
e 
re
al
ly
 n
ic
e 
to
 a
ct
ua
lly
 h
av
e 
so
m
e 
ki
nd
 o
f c
on
si
st
en
cy
. A
t 
le
as
t 
if 
w
e 
co
ul
d
 a
gr
ee
 o
n 
ce
rt
ai
n 
ar
ea
s,
 c
er
ta
in
 o
ut
co
m
es
 t
ha
t 
w
e 
co
ul
d
 d
efi
ne
. (
C
an
ad
a)
 0
08
Fa
tig
ue
 a
nd
 e
ne
rg
y,
 t
he
 p
ro
b
le
m
 is
, h
ow
 d
o 
yo
u 
d
efi
ne
 t
ha
t,
 a
nd
 m
ak
e 
su
re
 t
ha
t 
d
efi
ni
tio
n 
ho
ld
s 
tr
ue
 a
cr
os
s 
al
l s
tu
d
ie
s 
an
d
 c
en
tr
es
? 
Th
at
’s
 t
he
 
p
ro
b
le
m
. I
t’
 a
 c
om
b
in
at
io
n 
of
 o
ut
co
m
es
 t
ha
t 
ar
e 
im
p
or
ta
nt
, b
ut
 a
ls
o 
on
es
 t
ha
t 
ca
n 
b
e 
d
efi
ne
d
 t
ig
ht
ly
 e
no
ug
h 
to
 b
e 
m
ea
ni
ng
fu
l. 
(U
K
) 0
12
A
t 
a 
hi
gh
 le
ve
l i
t’s
 v
er
y 
ea
sy
 t
o 
d
is
cu
ss
 t
he
se
 t
hi
ng
s,
 a
t 
a 
m
or
e 
d
et
ai
le
d
 le
ve
l i
t 
st
ar
ts
 t
o 
b
ec
om
e 
co
m
p
lic
at
ed
. C
ar
d
io
lo
gy
 h
av
e 
b
ee
n 
q
ui
te
 g
oo
d
 
at
 t
hi
s 
m
uc
h 
m
or
e 
th
an
 c
an
ce
r 
ha
ve
, w
e 
ne
ed
 t
o 
ge
t 
m
or
e 
lik
e 
ca
rd
io
lo
gy
 t
ria
ls
. T
he
y 
d
es
cr
ib
e 
so
m
et
hi
ng
 t
ha
t 
m
ea
ns
 s
om
et
hi
ng
 t
o 
d
oc
to
rs
, 
p
ro
fe
ss
io
na
ls
, a
nd
 in
 t
he
 s
am
e 
d
om
ai
n,
 m
ea
ns
 s
om
et
hi
ng
 im
p
ac
tf
ul
 b
ut
 d
iff
er
en
t 
to
 p
at
ie
nt
s.
 Id
ea
lly
 y
ou
 n
ee
d
 t
o 
ha
ve
 s
om
et
hi
ng
 t
ha
t 
ac
tu
al
ly
 
m
ak
es
 s
en
se
 t
o 
p
at
ie
nt
s 
th
at
 m
ak
es
 s
en
se
 t
o 
th
e 
p
ub
lic
. (
U
K
) 0
26
 
       E
as
ily
 m
ea
su
ra
b
le
Th
e 
ch
al
le
ng
es
 w
ill
 d
ep
en
d
 o
n,
 t
o 
so
m
e 
ex
te
nt
, h
ow
 d
iffi
cu
lt 
is
 it
 t
o 
m
ea
su
re
 t
ho
se
 e
le
m
en
ts
, i
f t
he
 m
ea
su
re
m
en
t 
is
 v
er
y 
ha
rd
, i
t’s
 g
oi
ng
 t
o 
b
e 
m
or
e 
ch
al
le
ng
in
g 
an
d
 c
os
tly
 t
o 
ca
p
tu
re
, s
o,
 t
ha
t’s
 p
ro
b
ab
ly
 g
oi
ng
 t
o 
b
e 
th
e 
b
ig
ge
st
 d
ow
ns
id
e,
 is
 c
an
 y
ou
 e
ffi
ci
en
tly
 m
ea
su
re
 t
ho
se
 t
hi
ng
s 
in
 s
tu
d
ie
s?
 
(C
an
ad
a)
 0
07
W
el
l m
ay
b
e 
w
ha
t 
th
e 
p
at
ie
nt
’s
 t
el
lin
g 
yo
u 
fa
tig
ue
/e
ne
rg
y 
is
 a
 q
ui
te
—
it’
s—
al
so
 a
 s
of
t 
b
ut
 a
 r
el
ev
an
t 
en
d
 p
oi
nt
—
ho
w
 w
ou
ld
 y
ou
 m
ea
su
re
 t
ha
t 
en
er
gy
/f
at
ig
ue
? 
(A
us
tr
ia
) 0
59
 
       R
eq
ui
rin
g 
m
in
im
al
 
re
so
ur
ce
s
B
ut
 if
 fo
r 
so
m
e 
re
as
on
 y
ou
 d
on
’t 
ha
ve
 t
he
 b
ud
ge
t 
or
 t
he
 t
im
e 
or
 t
he
 r
es
ou
rc
es
 t
o 
d
o 
it,
 I 
d
on
’t 
th
in
k 
w
e 
sh
ou
ld
 p
ut
 a
 b
la
ck
 m
ar
k 
on
 t
ha
t 
tr
ia
l a
nd
 
sa
y,
 o
h 
th
at
 t
ria
ls
 n
ot
 a
s 
go
od
 a
s 
it 
sh
ou
ld
 b
e,
 it
 d
oe
sn
’t 
m
ee
t 
ou
r 
st
an
d
ar
d
s 
an
d
 s
o 
th
er
e’
s 
go
in
g 
to
 b
e 
so
m
e 
ed
ito
ria
l b
oa
rd
s 
th
at
 d
on
’t 
p
ub
lis
h 
a 
re
al
ly
 g
oo
d
 s
tu
d
y.
 I 
d
ou
b
t 
th
at
’s
 g
oi
ng
 t
o 
ha
p
p
en
 b
ut
 it
’s
 s
om
et
hi
ng
 t
ha
t 
ca
n 
ge
t 
ou
t 
of
 c
on
tr
ol
 h
er
e.
 (U
S
A
) 0
03
If 
th
e 
m
ea
su
re
m
en
t 
is
 v
er
y 
ha
rd
, i
t’s
 g
oi
ng
 t
o 
b
e 
m
or
e 
ch
al
le
ng
in
g 
an
d
 c
os
tly
 t
o 
ca
p
tu
re
, s
o,
 t
ha
t’s
 p
ro
b
ab
ly
 g
oi
ng
 t
o 
b
e 
th
e 
b
ig
ge
st
 d
ow
ns
id
e,
 is
 
ca
n 
yo
u 
ef
fic
ie
nt
ly
 m
ea
su
re
 t
ho
se
 t
hi
ng
s 
in
 s
tu
d
ie
s?
 (C
an
ad
a)
 0
07
Ta
b
le
 2
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T
he
m
e
Q
uo
ta
ti
o
ns
 
       C
re
at
in
g 
a 
cu
ltu
re
 
sh
ift
It’
s 
a 
gr
ea
t 
p
us
h,
 t
o 
cr
ea
te
 a
 c
ul
tu
re
 is
 k
ey
. Y
ou
 w
an
t 
a 
re
al
 g
en
ui
ne
 in
te
re
st
 in
 t
hi
s 
ty
p
e 
of
 r
es
ea
rc
h,
 a
nd
 I 
th
in
k 
yo
u 
fo
st
er
 t
ha
t 
b
y 
fu
nd
in
g 
th
is
 
ki
nd
 o
f r
es
ea
rc
h,
 e
as
ily
 d
on
e.
 T
he
 n
ex
t 
th
in
g 
yo
u 
kn
ow
 t
he
re
’s
 g
oi
ng
 t
o 
b
e 
a 
p
le
th
or
a 
of
 r
es
ea
rc
he
rs
 in
te
re
st
ed
 in
 p
at
ie
nt
 c
en
tr
ed
 o
ut
co
m
es
 if
 y
ou
 
ac
tu
al
ly
 fu
nd
 it
. (
U
S
A
) 0
03
It 
m
ak
es
 s
en
se
 if
 t
hi
s 
is
 c
oo
rd
in
at
ed
 w
ith
 t
he
 fu
nd
in
g.
 If
 t
he
re
 is
 a
 c
al
l t
o 
d
ev
el
op
 t
oo
ls
 t
o 
m
ea
su
re
 t
he
 fu
nc
tio
na
l i
nd
ep
en
d
en
ce
 in
 d
ia
ly
si
s,
 s
o 
if 
it 
le
ad
s 
to
 t
ha
t 
fo
r 
th
e 
re
se
ar
ch
er
s,
 it
 is
 im
p
or
ta
nt
. A
nd
 t
he
n 
I w
ou
ld
 s
ay
 t
ha
t 
th
at
 is
 u
se
d
 o
nc
e,
 v
al
id
at
ed
, a
nd
 it
 b
ec
om
es
 im
p
or
ta
nt
 fo
r 
th
e 
p
at
ie
nt
s.
 
B
ec
au
se
 y
ou
 m
ig
ht
 u
nd
er
st
an
d
 w
ha
t 
ki
nd
 o
f i
nt
er
ve
nt
io
ns
 c
an
 m
ak
e 
th
e 
fu
nc
tio
na
l i
nd
ep
en
d
en
ce
 b
et
te
r, 
m
ai
nt
ai
n 
b
et
te
r 
ov
er
 t
im
e.
 (C
an
ad
a)
 0
09
It 
al
m
os
t 
re
q
ui
re
s 
a 
sh
ift
 in
 m
in
d
se
t 
of
 c
lin
ic
ia
ns
 o
f w
ha
t 
w
e’
re
 a
ct
ua
lly
 t
ry
in
g 
to
 a
ch
ie
ve
 w
he
n 
w
e 
d
ia
ly
se
 p
eo
p
le
, b
ec
au
se
 c
lin
ic
ia
ns
 h
av
e 
ju
st
 
b
ee
n 
fo
cu
se
d
 o
n 
nu
m
b
er
s 
an
d
 b
lo
od
 r
es
ul
ts
. (
U
K
) 0
17
 
       A
ve
rs
io
n 
to
 
in
te
ns
ify
in
g 
b
ur
ea
uc
ra
cy
Yo
u 
ge
t 
d
is
co
ur
ag
ed
, i
t 
se
em
s 
lik
e 
th
er
e’
s 
a 
b
un
ch
 o
f r
eg
ul
at
io
ns
. I
 v
al
ue
 t
he
se
 o
ut
co
m
es
, I
 t
hi
nk
 t
he
y’
re
 im
p
or
ta
nt
, t
he
y’
re
 u
nd
er
st
ud
ie
d
, w
e 
ne
ed
 
to
 c
ha
ng
e 
fu
nd
in
g 
m
ec
ha
ni
sm
s.
 W
e 
ne
ed
 a
 r
ev
ol
ut
io
n,
 b
ut
 it
’s
 t
o 
co
m
p
el
 r
es
ea
rc
he
rs
 t
o 
in
cl
ud
e,
 y
ou
 m
us
t 
ha
ve
 t
hi
s 
as
se
ss
m
en
t 
to
ol
 in
 y
ou
r 
tr
ia
l, 
I’m
 n
ot
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would alleviate financial impact, though some remarked 
that whether an outcome was ‘alterable’ (ie, potentially 
responsive to an intervention), could be difficult to deter-
mine without having been assessed in the first place. It 
was also contended that large trials were often trying to 
answer questions that were too ‘black and white’ and 
thus consistently showed no difference in mortality and 
morbidity, and some suggested that a ‘marked difference 
in patient experience’ may be more likely to be seen and 
relevant to report as an outcome in a trial.
Differentiating between treatments
Some thought core outcomes had to be potentially 
responsive to the intervention to detect existing differ-
ences and were uncertain about ‘mandating [specific 
outcomes] necessarily, unless the intervention was inter-
ested in it’.
reflective of economic burden on healthcare
Participants considered outcomes that imposed substan-
tial economic burdens on patients and the health system, 
such as hospitalisation and vascular access complications 
should be included as core outcomes.
Feasibility for implementation
Clarity and consistency in definition and interpretation
Developing standardised definitions for core outcomes 
was expected to be challenging and require detailed 
thought as the core outcome would have to ‘mean some-
thing to doctors, professionals and to mean something 
impactful to patients’ and ‘hold true across all studies and 
centres’.
Easily measurable
Participants emphasised that core outcomes should be 
relatively easy to measure in a ‘valid, meaningful way with 
minimal bias’ so that it could be assessed in ‘multiple 
settings across the world.’ For dimensions of quality of 
life such as fatigue, they suggested that patients should 
be able to report it but also expressed uncertainty about 
what measures were appropriate and validated for use in 
this setting.
Requiring minimal resources
Some participants were wary about mandating core 
outcomes that would require added cost and burden on 
researchers and patients—‘if for some reason you don’t 
have the budget or the time or the resources to do it, I 
don’t think we should put a black mark on that trial’.
Creating a culture shift
Participants believed that the uptake of core outcomes 
should be inspired by ‘real genuine interest’ and should 
happen ‘organically’ through a change in culture. They 
suggested coordinated and targeted funding towards 
studies that address the core outcomes and to shift the 
mindset of clinicians from numbers and blood results 
that are easy to measure, to focusing on outcomes that 
patients are interested in.
Aversion to intensifying bureaucracy
There was some concern and hesitation about enforcing 
the use of core outcomes as it was perceived to add 
bureaucratic pressure on investigators and may ‘deflate 
and deter them [ie, residents and fellows] from pursuing 
research’ as they had other pressing priorities to contend 
with.
Allowing justifiable exceptions
Some advocated that using core outcomes should come 
with a ‘proviso’ as a ‘trial may not be designed to measure 
them [the core outcomes], but if they still have to report 
them, it may not be received as well’.
Authoritative inducement and directive
Endorsement for legitimacy
Providing endorsed measures for outcomes was antici-
pated to be an effective strategy for facilitating the accep-
tance and use of core outcomes in trials.
Necessity of buy-in from dialysis providers
Dialysis providers (ie, industry) were identified as gate-
keepers to the implementation of core outcomes—‘if you 
come up with a bunch of core outcomes that industry says 
we cannot deliver these, you might as well go home’. At 
the same time, some predicted that the dialysis industry 
would be unlikely to object to outcomes that reflected 
what patients and physicians considered important in 
order to avoid ‘terrible publicity’.
Incentivising uptake
In principle, ‘tying payment’ to core outcomes would be 
effective and incentives could be given to exemplary units. 
Another participant suggested that core outcomes should 
be able to be commissioned—‘you could commission 
around renal failure and hospitalization, and vascular 
utilization…I could commission for how much travel the 
patients have done and I would put in inducements to 
support travel for people on haemodialysis’.
Instituting patient-centredness
Explicitly addressing patient-important outcomes
Some expected that implementing core outcomes would 
shift current clinical practice towards an explicit focus on 
patient-centred care—‘the most obvious reason to have 
a set of core outcomes is that we should enforce or at 
least try to provide care to all of our patients such that 
all of these core outcomes are met. I’m glad that some-
body’s going to do trials about them, but more impor-
tantly, I want our patients to realise, or notice that, we are 
listening to what they think is important to them’.
Reciprocating trial participation
Reporting core outcomes was seen to align with ethics of 
research conduct—‘patients give us their time and effort 
to participate in the trial, they need to get something out 
of that, that is valuable to them’.
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Improving comparability of interventions for decision-making
Participants were aware of the heterogeneity of outcomes 
that prevented their ability to assess the comparative 
effect of interventions—‘we need to be comparing 
apples with apples; we’re talking about meta-analyses and 
getting a fruit salad’. Having standardised outcomes that 
were consistently reported would allow them to make 
informed decisions based on the totality of the available 
trial evidence.
Driving quality improvement
Although core outcomes would be primarily established 
for trials, some participants believed it would support 
quality improvement initiatives and inform ways to 
modify approaches to clinical care and address outcomes 
that matter to patients and clinicians.
Compelling a focus on quality of life
Participants expected that a core quality of life outcome 
would translate into routine clinical practice and prompt 
nephrologists to undertake explicit and systematic assess-
ment of patient concerns and priorities. It provided an 
opportunity to align goals as ‘physicians and scientists 
look at the world differently than the patient does’. 
Some participants remarked that this would ‘force a 
lot of providers who see their patients like cattle, a way 
of making money…a sort of billing code’ to address 
patient-centred outcomes.
COnClusIOn
Nephrologists supported the need for a consensus-based 
core outcome set to be reported in every trial in haemo-
dialysis to enable treatment decisions based on outcomes 
that were regarded as important to patients and clini-
cians. They agreed that core outcomes should have direct 
relevance and impact on patients, which necessitated the 
inclusion of mortality, well-being and functioning, serious 
comorbidities (namely cardiovascular disease) and other 
indicators of treatment success. The implications to 
healthcare resource of including the outcomes in trials 
were considered, as was the plausibility of the outcome 
being able to measure the benefits and harms (effective-
ness) of an intervention. Nephrologists emphasised that 
core outcomes must be broadly applicable across health-
care jurisdictions and patient populations, particularly in 
low-income and non-English speaking countries.
To ensure feasibility for implementing core outcomes, 
nephrologists suggested providing clear and consistent 
definitions for the outcome, making available valid and 
simple measures that can be used across all trials, creating 
a cultural shift through targeted funding schemes for 
research that address core outcomes and minimising 
bureaucratic burden on researchers. They believed 
endorsement, buy-in from gatekeeper stakeholders (eg, 
dialysis providers) and incentivisation would support 
implementation. Nephrologists perceived core outcomes 
as an opportunity to strengthen patient-provider 
communication, shared decision making education and 
patient-focused research by providing a mechanism 
for researchers and clinicians to explicitly address the 
patients’ well-being, defining targets for quality improve-
ment and improving the consistency and relevance of 
evidence to inform shared decision about treatment.
Broadly, the types of outcomes suggested by nephrolo-
gists are similar to the OMERACT core areas of death, life 
impact (how a patient feels or functions), pathophysiolog-
ical manifestations (disease-specific clinical and psycho-
logical signs, biomarkers and potential surrogate outcome 
measures) and resource use (financial and other costs 
of the health condition and interventions).22 However, 
establishing a core outcome set was perceived by nephrol-
ogists as an endeavour to focus much needed attention 
towards patient-reported outcomes, clinical outcomes 
(eg, cardiovascular disease) and treatment complications 
(eg, vascular access problems), rather than biochemical 
parameters such as serum phosphate, calcium and para-
thyroid hormone. This may reflect concerns about the 
widespread use of non-validated biochemical outcomes in 
trials and clinical practice in nephrology.23 24 In relation 
to the core area of ‘resource use’, nephrologists consid-
ered the burden of comorbidities and treatment compli-
cations on healthcare consumption (eg, hospitalisation) 
but did not explicitly suggest including economic evalua-
tions as a core outcome.
Nephrologists also raised principles that reflect compo-
nents of the OMERACT Filter for the development and 
validation of outcome measures: truth (measures what is 
intended and is unbiased and relevant), discrimination 
(reliability and sensitivity to change) and feasibility1 as 
well as items in the recent COMET-Consensus-based Stan-
dards for the selection of health Measurement Instru-
ments (COSMIN) guidelines.8 A challenge raised by 
nephrologists was the lack of validated and appropriate 
patient-reported outcome measures for use in patients on 
haemodialysis.25–27 Some also argued that interventions 
may not be targeted at improving quality of life outcomes. 
This highlights a tension between responsiveness to an 
intervention and importance as the basis for identifying 
a core outcome. While responsiveness to an intervention 
may be important to triallists, patients and caregivers 
want to know about the impact of outcomes that matter 
to them—even if the trial shows no difference.28
The COSMIN-COMET guideline stipulates ‘regulatory 
agency’s requirement for approval’ as a feasibility aspect8 
and while this may have helped to improve the uptake of 
the OMERACT core outcomes for rheumatoid arthritis,10 
some nephrologists were concerned about the potential 
burden on researchers. In addition to COSMIN-COMET 
feasibility items, nephrologists suggested that advocacy or 
endorsement by external agencies or setting up targeted 
funding calls to address core outcomes may promote a 
cultural shift to support the uptake of core outcomes. Of 
note, the UK National Institute for Health Research guid-
ance for grant applications advises researchers to include 
core outcomes in their proposal.29 Similarly, the UK 
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Marie Curie Research Grants scheme (total US$2 million) 
recently sought proposals for research priorities identi-
fied by a research priority partnership with patients and 
health professionals in palliative and end-of-life care.30 
We suggest that targeted or prioritised funding for trials 
or research proposals that address core outcomes would 
be conceivable and effective for implementation.
Our study provides novel empiric data about the 
perspectives of nephrologists on core outcomes: what 
they, in principle, believe should be included as core 
outcomes, considerations for feasibility for implemen-
tation and the expected impact of core outcomes. We 
used purposive sampling and obtained a diverse range 
of demographic characteristics and clinical and research 
experience. However, our study has some potential limita-
tions. The transferability of the findings to low-income 
settings is uncertain as the participants were from high-in-
come countries. However, they emphasised cross-cultural 
applicability and validity as a key consideration in estab-
lishing core outcomes. We acknowledge that these data 
were collected prior to establishing the core outcome 
set for haemodialysis. Therefore, perspectives on imple-
menting the specific cores outcomes for haemodialysis 
that have since been established (eg, cardiovascular 
disease, fatigue, mortality, vascular access function) may 
not have been specifically discussed. However, clinician’s 
perspectives on implementing the specific core outcomes 
have been detailed in subsequent workshop reports.17 31 32 
Also, we only included nephrologists in the study, though 
the similarities with broader frameworks1 3 8 22 for estab-
lishing and implementing core outcomes suggest that the 
findings may be relevant to other populations and disease 
and healthcare settings. Other healthcare providers, 
policy makers and service users will be involved in other 
phases of SONG-HD.17 31 32
In recent years, there have been calls to establish core 
outcomes in nephrology.33 34 Using the COMET and 
OMERACT methodology framework for establishing 
core outcomes (ie, systematic review, nominal group 
technique, stakeholder interviews Delphi surveys and 
consensus workshops),3 35 the SONG-HD Initiative has 
engaged over 1300 stakeholders (including patients/
caregivers and health professionals) from more than 70 
countries to establish core outcome domains for trials in 
haemodialysis: mortality, cardiovascular disease, fatigue 
and vascular access.16–19 36 These echo the outcomes 
nephrologists expected to be included in the core 
outcome set, though the SONG-HD process identified 
fatigue as a critically important specific patient-reported 
outcome because of its profound impact on patients’ 
well-being and functioning.16 17 Establishing feasible and 
valid core outcome measures are now in progress.28 More-
over, actions to facilitate implementation are underway. 
We are inviting endorsement by professional organisa-
tions, guideline groups and trial networks and convening 
implementation workshops involving a broader range 
of stakeholders including representatives from regula-
tory and policy agencies, industry, patient organisations, 
professional societies, research organisations, registries, 
trial networks and funding bodies.28
Ensuring a parsimonious set of simple, consistent and 
valid core outcome measures and creating a cultural shift 
such as through targeted funding to address the outcomes 
may facilitate the use of outcomes. Also, garnering buy-in 
and support from regulatory agencies, ‘gatekeepers’ 
and other key stakeholder organisations were recom-
mended by nephrologists to enable and promote wide-
spread implementation of core outcomes. Integrating 
these in the implementation strategy and action plan for 
core outcomes will improve the consistency of reporting 
critically important outcomes across trials. This may ulti-
mately improve the contribution of trial-based evidence 
to advance patient-centred care and outcomes.
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